For the treatment and prevention of tick, flea and mite infestations in dogs. Bravecto® kills adult, and juvenile ticks (larvae and nymphs). Bravecto® can be used as part of a treatment strategy for flea allergy dermatitis (FAD). For the treatment of Demodicosis caused by Demodex spp. and Sarcoptic mange mites. In a controlled trial, treatment with fluralaner resulted in the complete removal of Demodex spp. mites from treated dogs. For the treatment of Otodectes spp. ear mite infestations. The flea insecticidal efficacy of Bravecto® (fluralaner) significantly reduces the likelihood of Dipylidium caninum (tapeworm) transmission from fleas to susceptible dogs throughout the 84 days following a single treatment, by controlling fleas on dogs and lowering the flea burden in the dog’s immediate environment.

WARNINGS

• Use with caution in dogs with pre-existing epilepsy.

• Safety in puppies less than 8 weeks of age and/or dogs weighing less than 2 kg has not been established.

• For dogs infected with tapeworm, it is recommended that a suitable tapeworm treatment be used.

• Keep Bravecto® in the original packaging until use.

• Do not use in case of hypersensitivity to fluralaner or to any of the excipients.

• KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.

• Can be used in breeding, pregnant and lactating dogs.

• Bravecto® is well tolerated in MDR1 dogs following oral administration.

• Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS

• Do not eat, drink or smoke while handling the product.

• Wash hands thoroughly with soap and water immediately after use of the product.

• Do not store with food, drinks, medication or household products.

• Do not administer at intervals shorter than 8 weeks as the safety for shorter intervals has not been tested.